Ask about this productRelated genes to: DGKH Blocking Peptide
- Gene:
- DGKH NIH gene
- Name:
- diacylglycerol kinase eta
- Previous symbol:
- -
- Synonyms:
- DGKeta
- Chromosome:
- 13q14.11
- Locus Type:
- gene with protein product
- Date approved:
- 2004-04-16
- Date modifiied:
- 2016-10-05
Related products to: DGKH Blocking Peptide
Related articles to: DGKH Blocking Peptide
- NRAS mutations occur in 10%-30% of cutaneous melanomas and are associated with high tumor mutational burden. Mutant NRAS signaling drives aberrant cell growth and proliferation, in part, through activation of the RAF-MEK-ERK1/2 kinase pathway; however, targeted therapies to this pathway have limited effectiveness in patients with NRAS mutant melanoma. The role of other targetable signaling pathways in NRAS mutant melanoma is poorly characterized. Here, we demonstrated that one isoform of diacylglycerol kinase, diacylglycerol kinase eta (DGKη), a lipid signaling regulator, was highly expressed in NRAS mutant melanoma patient samples. Knockdown of DGKH in NRAS mutant melanoma cell lines resulted in significant growth inhibition in vitro. Transcriptomic data indicated downregulation of the estrogen response late signature, including decreased CCND1 (cyclin D1) expression following DGKH knockdown. Cell growth inhibition and decreased cyclin D1 expression correlated to an inhibition of cell cycle after DGKH knockdown. These data suggest that DGKη mediates cell cycle progression in NRAS mutant melanoma cells and represents a potential therapeutic target for these patients. - Source: PubMed
Wilson Haley PStefanski Casey DCaksa SigneMersky Glenn LVarney Scott DHaj Jelan IErkes Dan APurwin Timothy JChua VivianAplin Andrew E - More and more people are traveling to tropical and subtropical regions, whether for business or pleasure. Therefore, sound travel medicine advice is an essential part of preventive healthcare. This advice includes vaccination recommendations, malaria prophylaxis, individual risk assessment, education, and up-to-date interdisciplinary knowledge. This knowledge is especially important for vulnerable groups, such as pregnant women, children, and people with chronic illnesses. - Source: PubMed
Publication date: 2026/04/20
Frühwein MarkusSchelling JörgWendt Sebastian - Background Carpal tunnel syndrome is a neuropathic compressive condition caused by median nerve compression as it travels into the wrist through the carpal tunnel. Validated patient-reported outcome measures such as the Quick Disabilities of the Arm, Shoulder, and Hand (QuickDASH) and the Mayo Wrist Score are commonly used to assess outcomes following carpal tunnel release; however, limitations remain in interpreting whether observed score changes are clinically meaningful from the patient's perspective. The primary objective of this study was to determine the minimal clinically important difference (MCID) and substantial clinical benefit (SCB) for the Mayo Wrist Score after isolated carpal tunnel release, and secondarily to contextualize postoperative QuickDASH change using previously reported clinically meaningful thresholds. Methodology This prospective study included adult patients undergoing isolated carpal tunnel release at two tertiary hospitals. QuickDASH and Mayo Wrist Scores were recorded preoperatively and at the six-month follow-up. MCID and SCB were calculated using anchor-based and distribution-based methods, with receiver operating characteristic curve analysis primarily applied to the Mayo Wrist Score Results A total of 92 patients were enrolled, of whom 73 completed the six-month follow-up. The anchor-based MCID for the Mayo Wrist Score was 11.5 points (area under the curve (AUC) = 0.77), while the SCB threshold was 13.5 points (AUC = 0.91). Significant postoperative improvements were observed in both QuickDASH and Mayo Wrist Scores. Conclusions Establishing MCID and SCB values for the Mayo Wrist Score and contextualizing change in the QuickDASH score provides a clinically meaningful framework for interpreting patient-reported outcomes following carpal tunnel release. - Source: PubMed
Publication date: 2026/03/17
Al Balushi AmmarAl Lawati AbdullahShummo MoathAl Badi MarwaAl Furqani AsmaaAl Wahaibi Ahmed MAl-Nizwani WaleedAl-Muqaimi Nawaf AAl Ghaithi Ahmed - The S2K guideline, organized by the German Respiratory Society, is aimed at physicians in Germany, Switzerland, and Austria who perform outpatient or inpatient diagnostic flexible bronchoscopy in adult patients. Its goal is to standardize the procedure, minimize complications, and improve diagnostic safety. The guideline specifically addresses specialists in pulmonology, thoracic surgery, and hospital hygiene, as well as nursing and technical staff. It provides evidence- and consensus-based recommendations on indications, preparation, execution, hygiene measures, and aftercare. Additionally, it serves as an information resource for physicians from other specialties, payers, professional societies, and can support quality management. It applies to medical care in Germany, Austria, and Switzerland and incorporates the latest scientific findings up to the date of publication. - Source: PubMed
Publication date: 2026/03/24
Hübner Ralf-HartoHetzel JürgenBaysal BarbaraBoeing SebastianDarwiche KaidEberhardt RalfEisenmann StephanFranke Karl-JosefGesierich WolfgangGompelmann DanielaHeindl StefanHerth FelixHetzel MartinHolland AngéliqueKahnert KathrinLoop TorstenMartiny HeikePizarro CarmenQuadder BerndRichter ThomasSchmidt-Planck ChristianStanzel FranzSteinack CarolinWelcker KatrinWustrack StefanieHagmeyer Lars - - Source: PubMed
Publication date: 2025/11/01
Cai FeifanZhao Bixing